Skip to content
  • Sunday, 26 July 2026
  • 4:31 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Europe Must Rethink Funding and De-Risk Assets to Secure its Rare Disease Research Pipeline
Pharmaceutical R&D

Europe Must Rethink Funding and De-Risk Assets to Secure its Rare Disease Research Pipeline

Teuku Ryan Jun 13, 2026 0

The 13th European Conference on Rare Diseases and Orphan Products, held in Prague, Czech Republic, from June 3-4, 2026, served…

Read More
Data Science & Bioinformatics

Leveraging Mimesis for Secure Data Science: A Comprehensive Guide to Anonymizing Production Data.

Evan Lee Salim May 20, 2026 0

In an increasingly data-driven world, the ability to harness the power of vast datasets is paramount for innovation, yet it…

Read More
Pharmaceutical R&D

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings – Pharmaceutical Technology

Teuku Ryan Apr 25, 2026 0

The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…

Read More
Pharmaceutical R&D

Pfizer and Astellas Secure FDA Priority Review for Perioperative Padcev and Keytruda Combination in Muscle-Invasive Bladder Cancer

Teuku Ryan Apr 21, 2026 0

The United States Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) from…

Read More
Pharmaceutical R&D

MSD’s $6.7 Billion Acquisition of Terns Pharmaceuticals Signals a Bold Strategic Pivot in Oncology to Secure Future Growth

Teuku Ryan Mar 31, 2026 0

On March 25, Merck & Co. (MSD) announced a significant strategic move, acquiring Terns Pharmaceuticals for an estimated $6.7 billion…

Read More
Science News, founded in 1921, continues its mission to provide accurate information on scientific advancements.The Alarming Rise of Unregulated Weight Loss Medications in the UK: A Public Health Crisis in the MakingUnderwater compressed air effectively removes coral species invasive to BrazilUnveiling Earth’s Hidden Infrastructure: First Global Maps Reveal the Vast Scale of Underground Fungal Networks Crucial for Climate Regulation
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ